|
|
| (7 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| {{West nile virus}}
| | #redirect [[West nile virus infection medical therapy]] |
| {{CMG}}; {{AE}} {{AL}}
| |
| | |
| ==Overview==
| |
| There is no specific [[antiviral]] treatment for west nile virus infection. Current management of these patients is based on supportive care towards [[symptom]] relief and prevention of [[complications]].
| |
| | |
| ==Medical Therapy==
| |
| ===Supportive care <small><small><small><small>Adapted from CDC<ref name="CDC">{{cite web| url= http://www.cdc.gov/westnile/healthCareProviders/healthCareProviders-TreatmentPrevention.html| title= CDC Treatment and Prevention}}</ref></small></small></small></small>===
| |
| * There is no specific [[antiviral]] therapy indicated in patients with west nile virus infection.
| |
| * Treatment consist of supportive measurements and prevention of complications.
| |
| * In severe cases, patients often need to be hospitalized to receive supportive treatment, such as [[intravenous fluids]], [[analgesics]], and nursing care.
| |
| *Patients with severe meningeal symptoms often require pain control for [[headaches]] and antiemetic therapy and rehydration for associated [[nausea]] and [[vomiting]].
| |
| *Patients with [[encephalitis]] require close monitoring for the development of elevated [[intracranial pressure]] and [[seizures]].
| |
| *Patients with [[encephalitis]] or [[paralysis]] should be monitored for inability to protect their airway.
| |
| *Acute neuromuscular [[respiratory failure]] may develop rapidly and prolonged ventilatory support may be required.
| |
| | |
| ===Medications===
| |
| *Although various drugs have been evaluated or empirically used for WNV disease, none have shown specific benefit to date.
| |
| *There are no guidelines that recommend the use of [[ribavirin]] or [[interferon alfa-2b]] for the treatment of west nile virus encephalitis or meningitis.<ref name="TunkelGlaser2008">{{cite journal|last1=Tunkel|first1=Allan R.|last2=Glaser|first2=Carol A.|last3=Bloch|first3=Karen C.|last4=Sejvar|first4=James J.|last5=Marra|first5=Christina M.|last6=Roos|first6=Karen L.|last7=Hartman|first7=Barry J.|last8=Kaplan|first8=Sheldon L.|last9=Scheld|first9=W. Michael|last10=Whitley|first10=Richard J.|title=The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|volume=47|issue=3|year=2008|pages=303–327|issn=1058-4838|doi=10.1086/589747}}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |